Mainz Biomed and Praxisdienst form distribution partnership for ColoAlert

UNM’s Julie In awarded $1.9M to study uranium exposure on intestinal lining

Julie In received a $1.9 million grant from the National Institute of Environmental Health Sciences to study the impact of uranium on the cells that line the intestines.

December 13, 2024

Vol.50 No.46

Clinical Roundup

“Biological age” may predict early colorectal cancer risk

New research from Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine suggests that one’s biological age, which can be higher than his or her chronological age – a concept called accelerated aging – may predict who’s at risk for developing colon polyps, a known risk factor for colorectal cancer.

December 13, 2024

Vol.50 No.46

Drugs & Targets

MD Anderson, AmMax Bio announce agreements to develop immunotherapy for MRD-positive cancers

The University of Texas MD Anderson Cancer Center and AmMax Bio, Inc. announced a worldwide exclusive license agreement and clinical trial agreement to develop and advance AmMax’s AMB-066 monoclonal antibody therapy as a first-in-class treatment option for patients with colorectal cancer and minimal residual disease as well as those with MRD in other solid tumors.

December 13, 2024

Vol.50 No.46

Clinical Roundup

Home testing kits, coordinated outreach improve CRC screening rates

Colorectal cancer screening is an effective tool for catching the disease early when it’s most treatable, yet it is underutilized in patient populations who receive primary care at federally qualified health centers.

December 06, 2024

Vol.50 No.45

Drugs & Targets

Mainz Biomed and Thermo Fisher collaborate to develop next-gen global CRC screening product

Mainz Biomed, a molecular genetics diagnostic company specializing in the early detection of cancer, announced a collaborative agreement with Thermo Fisher Scientific Inc. through its subsidiary Life Technologies Corporation.

November 15, 2024

Vol.50 No.43

In Brief

Cathy Eng named associate director of strategic relations and research partnerships at Vanderbilt-Ingram

Cathy Eng, David H. Johnson Professor of Surgical and Medical Oncology, was named associate director of strategic relations and research partnerships for Vanderbilt-Ingram Cancer Center.

October 18, 2024

Vol.50 No.39

Mainz Biomed and Praxisdienst form distribution partnership for ColoAlert

YOU MAY BE INTERESTED IN

UNM’s Julie In awarded $1.9M to study uranium exposure on intestinal lining

“Biological age” may predict early colorectal cancer risk

MD Anderson, AmMax Bio announce agreements to develop immunotherapy for MRD-positive cancers

Home testing kits, coordinated outreach improve CRC screening rates

Mainz Biomed and Thermo Fisher collaborate to develop next-gen global CRC screening product

Cathy Eng named associate director of strategic relations and research partnerships at Vanderbilt-Ingram

Renew today!

Subscriber content

Never miss an issue!

Login